CONFIRMATION-HF

• Research type

  Research Study

• Full title

  Combined Efficacy and Safety of an Early, Intensive, Management Strategy With Finerenone and SGLT2 Inhibitor in Patients Hospitalized With Heart Failure (CONFIRMATION-HF)

• IRAS ID

  1010966

• Contact name

  Lisa Anderson

• Contact email

  lisa.anderson@stgeorges.nhs.uk

• Sponsor organisation

  CPC Clinical Research

• Eudract number

  2023-508874-27

• Clinicaltrials.gov Identifier

  NCT06024746

• Research summary

  Combination therapy of finerenone with empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
  Participation in this clinical trial will in no way preclude access to standard care for your patient. He/she will obtain the best opportunities for assistance and treatment currently available.
  Personal data of participants collected for the purpose of conducting the research will be treated in full compliance with the laws and regulations in force. The results of the study may be published, but patient‘s identity will not be disclosed.

• REC name

  East Midlands - Leicester Central Research Ethics Committee

• REC reference

  24/EM/0257

• Date of REC Opinion

  27 Feb 2025

• REC opinion

  Further Information Favourable Opinion